SUNOSI (solriamfetol hydrochloride) Axsome malta Patent: 10,351,517 Expiration: Jun 7, 2026 See More … For more information on how DrugPatentWatch
Drug Patent Expirations for the Week of June 7, 2026 Read Post »
AXIRON (testosterone) Eli lilly and co Patent: 8,993,520 Expiration: Jun 2, 2026 See More … For more information on how
Drug Patent Expirations for the Week of May 31, 2026 Read Post »
TOPICORT (desoximetasone) Sun pharma canada Patent: 8,715,624 Expiration: May 26, 2026 See More … For more information on how DrugPatentWatch
Drug Patent Expirations for the Week of May 24, 2026 Read Post »
A patent expiry for a blockbuster drug is not a legal event. It’s a commercial trigger. The twelve months before
Patent Analyst Suite vs Market Research: Why Pharma IP Teams Are Switching Read Post »
The biosimilar wave was supposed to be simple. Blockbuster biologics lose patent protection, cheaper copies enter the market, prices collapse,
The assumption is logical: if a tool costs nothing, you save money using it. That arithmetic breaks down badly when
Free Patent Databases Are Costing Pharma Teams $10K an Hour in Manual Labor Read Post »
Every year, generic pharmaceutical companies write off hundreds of millions of dollars on programs that were commercially viable on paper
Patent Data to Justify a $50M Generic Drug R&D Spend: The Exact Playbook Read Post »
The pharmaceutical industry loses about 80% of a brand’s revenue within twelve months of generic entry. For a blockbuster generating
The OTC Switch Window: Why You Need to Track Patents 10 Years Out Read Post »
When AbbVie watched its first Humira biosimilar land on the US market in January 2023, the company had already spent
Bio-Betters Are Eating Biosimilars: The Strategic Shift Reshaping Biologic Drug Patents Read Post »
Sign in or create a free account to read this DrugPatentWatch article
